Literature DB >> 31673552

Striving for decreased post-transplant hepatocellular carcinoma recurrence without excluding potentially curable patients: the utility of tumor biology.

Russell Evan Rosenblatt1, Karim Jarir Halazun1.   

Abstract

Entities:  

Year:  2019        PMID: 31673552      PMCID: PMC6791992          DOI: 10.21037/hbsn.2019.04.09

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  8 in total

1.  Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America.

Authors:  Federico Piñero; Matías Tisi Baña; Elaine Cristina de Ataide; Sergio Hoyos Duque; Sebastian Marciano; Adriana Varón; Margarita Anders; Alina Zerega; Josemaría Menéndez; Rodrigo Zapata; Linda Muñoz; Martín Padilla Machaca; Alejandro Soza; Lucas McCormack; Jaime Poniachik; Luis G Podestá; Adrian Gadano; Ilka S F Fatima Boin; Christophe Duvoux; Marcelo Silva
Journal:  Liver Int       Date:  2016-06-15       Impact factor: 5.828

2.  The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.

Authors:  Shaheed Merani; Pietro Majno; Norman M Kneteman; Thierry Berney; Philippe Morel; Gilles Mentha; Christian Toso
Journal:  J Hepatol       Date:  2011-02-18       Impact factor: 25.083

3.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.

Authors:  Christophe Duvoux; Françoise Roudot-Thoraval; Thomas Decaens; Fabienne Pessione; Hanaa Badran; Tullio Piardi; Claire Francoz; Philippe Compagnon; Claire Vanlemmens; Jérome Dumortier; Sébastien Dharancy; Jean Gugenheim; Pierre-Henri Bernard; René Adam; Sylvie Radenne; Fabrice Muscari; Filomena Conti; Jean Hardwigsen; Georges-Philippe Pageaux; Olivier Chazouillères; Ephrem Salame; Marie-Noelle Hilleret; Pascal Lebray; Armand Abergel; Marilyne Debette-Gratien; Michael D Kluger; Ariane Mallat; Daniel Azoulay; Daniel Cherqui
Journal:  Gastroenterology       Date:  2012-06-29       Impact factor: 22.682

4.  Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.

Authors:  Karim J Halazun; Marc Najjar; Rita M Abdelmessih; Benjamin Samstein; Adam D Griesemer; James V Guarrera; Tomoaki Kato; Elizabeth C Verna; Jean C Emond; Robert S Brown
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

5.  Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies.

Authors:  Karim J Halazun; Parissa Tabrizian; Marc Najjar; Sander Florman; Myron Schwartz; Fabrizio Michelassi; Benjamin Samstein; Robert S Brown; Jean C Emond; Ronald W Busuttil; Vatche G Agopian
Journal:  Ann Surg       Date:  2018-10       Impact factor: 12.969

6.  Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.

Authors:  Vincenzo Mazzaferro; Carlo Sposito; Jian Zhou; Antonio D Pinna; Luciano De Carlis; Jia Fan; Matteo Cescon; Stefano Di Sandro; He Yi-Feng; Andrea Lauterio; Marco Bongini; Alessandro Cucchetti
Journal:  Gastroenterology       Date:  2017-10-05       Impact factor: 22.682

7.  Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation.

Authors:  Michał Grąt; Jan Stypułkowski; Marcin Morawski; Karolina M Wronka; Michał Wasilewicz; Zbigniew Lewandowski; Karolina Grąt; Zofia Wójcik; Waldemar Patkowski; Krzysztof Zieniewicz
Journal:  Ann Surg       Date:  2020-06       Impact factor: 12.969

8.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.